MedTrace Logo

A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis

NCT03025542 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2026-03-24

Study results available
· View outcomes & findings →

Summary

This is a Phase 2a, multicenter, randomized, subject-blind, investigator-blind, study to investigate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis

Conditions

  • Chronic Plaque Psoriasis

Interventions

DRUG

Bimekizumab

Based on their randomization subjects will receive a combination of several injections of Bimekizumab.

OTHER

Placebo

Subjects will receive injections of Placebo.

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • UCB Biopharma SRL

    lead INDUSTRY

Principal Investigators

  • UCB Cares · 001 844 599 2273(UCB)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-27
Primary Completion
2017-12-11
Completion
2017-12-11
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Moldova

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03025542 on ClinicalTrials.gov